Skip to content
TrialScanner

NCT03813199

Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis

Phase 2CompletedABVXLead

Registry record

Lead sponsor
Abivax S.A.
Conditions
Rheumatoid Arthritis
Primary completion
Apr 27, 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03813199 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03813199: Study of Two Doses of ABX464... | TrialScanner